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ABSTRACT  
Objective: The aim of this scoping study was to identify gaps in the current literature and understand the T2DM and MIH comorbidity trends in the 
local population from the West Midlands, UK to inform future studies.  
Methods: This project was a scoping study of two parts; a critical review and a clinical audit. A thematic approach was used to group studies based 
on their overall study outcome. The clinical audit data was used to compare the local patient population to the patterns identified in the literature 
reviewed. 
Results: The reviewed studies reported a relationship between T2DM control and both depression and anxiety, but did not agree on its significance. 
The clinical audit of 71 patients diagnosed with T2DM showed that 73% of males presented with poor diabetes control (HbA1c>7) compared to 
females (46%). Conversely, females exhibited a higher prevalence of MIH (45%) compared to males (31%). 
Conclusion: From both this audit of the literature and local data, it remains unclear whether mental-ill health is a major driver for medication non-
adherence behaviour and uncontrolled diabetes. Further studies are recommended to further understand this comorbidity.  
Keywords: Anxiety, Depression, Type 2 diabetes mellitus, Mental ill-health, Real-world data 
© 2020 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open-access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) 
DOI: http://dx.doi.org/10.22159/ijpps.2020v12i2.36393.  Journal homepage: https://innovareacademics.in/journals/index.php/ijpps 
 
INTRODUCTION 
Type 2 Diabetes mellitus (T2DM) and its complications are 
increasing nationally and globally, consuming a large and increasing 
portion of health system expenditure [1, 2]. Depression and anxiety 
are mental health disorders that are frequently diagnosed in T2DM 
patients. Depression is referred to as a condition that ‘negatively 
affects how you feel, the way you think and how you act’ [3]. It may 
also impact on an individual’s emotional and physical state [3]. 
Anxiety, on the other hand, is defined as ‘feeling ‘uneasy’ or ‘on 
edge’, with overwhelming unrealistic worries and fear that can range 
between mild and severe’ [4]. In a systematic review, it was reported 
that ‘diabetic patients were twice as likely to be diagnosed with 
depression compared to people who do not have diabetes’ [5]. On 
the other hand, poor diabetes control was found to worsen the 
patient’s anxiety, which further worsened the diabetes control 
leading to further complications including depression [6, 7]. Jia et al., 
(2016) reported that a family history of depression and/or diabetes 
increases the possible association between the two conditions later 
in life, compared to the general population [8]. This highlighted the 
importance of screening for mental ill-health (MIH) in all patients 
diagnosed with diabetes [8]. Research has shown that a close focus 
on one condition can lead to other co-morbid conditions being 
overlooked. A study by Gonzalez et al., (2007) looked at depression, 
self-care and medication adherence in T2DM patients. They 
concluded that adherence to pharmacological therapy is important; 
suggesting that even low levels of depression may be associated 
with increased non-adherence to important aspects of diabetes self-
care [9]. Another meta-analysis which also looked at the association 
between MIH and T2DM concluded there is a connection between 
MIH and T2DM [10].  
MATERIALS AND METHODS 
This scoping study focused on depression and anxiety in T2DM 
patients. A total of 17 studies were critically reviewed (part 1) and 
the records of 71 patients were audited (part 2) to inform whether 
the local population shares the reported trends of T2DM, depression 
and anxiety found in the reviewed literature. Ethical approval was 
granted by the IRAS/HRA on 9/9/2019. 
RESULTS AND DISCUSSION 
Part 1–critical literature review 
A literature search was conducted using search engines such as 
Science Direct®, and Medline®. Search terms used were ‘anxiety’ 
‘depression’ and type 2 diabetes.’ The search was limited to 
literature from 2008-2019. The articles were screened for selection 
for further review. Fig. 1 shows the breakdown of how articles were 
selected during the preliminary search.  
All of the articles compared T2DM against occurrence of depression 
and or anxiety. A total of 20174 articles were identified; these were 
then further screened using the exclusion criteria, resulting in 17 
studies suitable for the part 1 critical review (Appendix 1). 
Studies included into the review were those that had their primary 
outcome as diabetes and non-adherence, diabetes and depression, 
diabetes and anxiety or diabetes and those including two or each of the 
three outcomes. Other studies were excluded. MIH is a broad term that 
fits a range of conditions. The CONSORT© (http://www.consort-
statement.org/) and CASP© https://casp-uk.net/ checklists were used 
as appropriate to determine the appropriateness and the quality of the 
studies for the inclusion in this review. 
The articles were further analysed to identify relationships reported 
between the comparators. Appendix 1 provides an overview of the 
studies’ designs and populations. A total of 17 articles were reviewed 
to assess the relationships reported between MIH and the effects of 
MIH on T2DM prognosis. The Cochrane© Handbook for Systematic 
Reviews of Interventions was used to guide the design of this review. 
Studies were analysed based on ten comparators (table 1), however, it 
was found that the study designs and primary outcomes varied widely, 
with no specific approach applied to investigate depression, anxiety 
with diabetes and non-adherence primary outcome. This indicates that 
a future multicentre large study is required to establish a better 
starting point with a robust and reproducible methodology. 
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Fig. 1: Inclusion and exclusion criteria or literature used 
 






































Gonzalez (9) N Y Y Y Y Y N Y N N 
Engum (10) Y Y Y Y N Y Y Y Y Y 
Lunghi (11) Y Y N Y N Y Y  N N N 
Mezuk (12) Y Y Y Y N Y Y Y Y N 
Ivanova (13) Y Y Y N N Y Y N N N 
Collins (14) Y Y N N N Y Y Y Y N 
Rachdi (15) N Y Y N N Y N N N N 
Edwards (16) Y Y Y Y N N N N N N 
Safren (17) N Y N Y Y Y N N N N 
Khuwaja (18) N Y Y Y N Y N N N N 
Ganasegeran 
(19) 
N Y N Y N Y N N N N 
Naicker (20)  Y Y Y Y N Y Y Y Y Y 
Ayman (21) N Y N Y Y Y N N N N 
Kivimaki (22) Y Y N N N N N N N Y 
Pan (23) Y Y N N N N N N N Y 
Pan (24) Y Y Y Y Y Y N N N N 
Roopan (25)  N N N Y Y Y Y N N N 
Eight out of the 17 studies included five or more of the ten identified comparators; however, the score was made up of different comparators, 
making it not possible to deem them to be comparable studies (fig. 2). 
 
 
Fig. 2: Journal bias total score 
Articles identified through 
search (n=20174) 
Articles excluded based on year group 
(n=12778) 
Articles screened (n=20174) 
Articles excluded based on 
clinical condition reviewed 
(n=20) 
Articles with full access (n=17) 
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Four studies [9-12] reached similar conclusions: ‘MIH has a 
substantial effect on T2DM prognosis and clinical deterioration of 
both conditions. These four studies demonstrate the association 
between MIH and T2DM has a negative impact on T2DM control and 
prognosis. 
Gonzalez et al., [9] stated that ‘depression increases the risk of 
poorer diabetes-specific outcomes such as hyperglycaemia and 
increased diabetic complications.’ The authors suggested that 
depression has a negative impact on T2DM when untreated. The 
authors added that ‘major depression is significantly associated with 
poorer diabetes self-care behaviour’ [9]. Engum et al., [10] in their 
study discussed the hypothesis that ‘symptoms of depression and 
anxiety are considered as significant risk factors for the onset of 
T2DM independent of all other known diabetes physical risk factors’. 
They asserted that people with untreated depression or anxiety will 
later potentially develop T2DM, noting the prevalence of depression 
is observed to be higher in the diabetic than the general population. 
Interestingly, this group suggested that ‘mood disturbance is a 
manifestation of the direct physiological effects of diabetes.’ Safren, 
et al., [11] added that cognitive behavioural therapy (CBT) improved 
adherence to medications for diabetes in patients diagnosed with 
depression and poorly controlled T2DM. This appears to support 
that MIH may have a deleterious effect on T2DM and that CBT may 
be an effective intervention for improving medication-taking 
behaviour. Pan et al., [12] concurred with Engum et al., [10] and 
added that patients with high depressive symptoms score had 
elevated risk of T2DM. Pan et al., [12] discussed finding that the 
incidence of depression was twice as high in diabetic patients as that 
in non-diabetic people and how ‘depression was associated with a 
60% increased risk for T2DM.’ Additionally, the authors reported 
that ‘the two conditions can cause or worsen each other.  
Six studies [13-18] discussed T2DM causing or worsening MIH such 
as depression and anxiety. Mezuk et al., [13] discussed the 
relationship of generalised anxiety disorder and its link with T2DM. 
The authors stated that ‘Major depression often co-occurs with 
chronic medical conditions such as T2DM’. Naiker et al., (2017) [14] 
found that the mortality rate increased dramatically when both 
conditions co-existed. They stated that ‘the relationship may 
alternately be conceptualised as an accumulation of risk over an 
individual’s lifetime through trajectories or chains of risk 
precipitated by psychiatric symptoms.’ Khawaja et al., (2010) [15] 
echoed Mezuk et al.,[13] and Naiker et al., [14] and agreed that 
T2DM influences the occurrence of MIH. Khawaja et al., [15] 
demonstrated that clinicians need to identify and treat anxiety and 
depression as ‘common components of diabetes care.' They also 
stated that 33% of people with diabetes experience clinical anxiety 
and 25% have clinical depression. Edwards LE [16] and Ayman et al., 
[17] also reported the association between T2DM and MIH, stating 
that in their study, anxiety and depression were twice as common 
among diabetic patients compared with matched control subjects 
without diabetes.  
Colins et al., [18] also concluded that the prevalence of anxiety and 
depression symptoms in patients with diabetes in their study 
sample was considerably higher than that in the general population. 
They noted that patients with diabetes complications who had poor 
medication adherence behaviour in their study, experienced higher 
levels of anxiety and/or depression; therefore, further affecting the 
primary condition. 
Lunghi et al., [19] described how T2DM and depression comorbidity 
was associated with worse self-care behaviour and poorer glycaemic 
control. The authors illustrated how diabetes and MIH affect each 
other’s prognosis causing further deterioration. Within their study 
sample, the incidence of a diagnosis of depression was higher during 
the first year after oral antidiabetic treatment was initiated. This 
demonstrates that the diagnosis of the T2DM may have be traumatic.  
Six studies [19-24] discussed the effect of antidepressant 
medications on T2DM diagnosis and prognosis due to their side 
effect of predisposing to metabolic disorders. Lunghi et al., [19] 
showed that patients prescribed antidepressant medications had a 
higher BMI (average 32.6, SD+/-= 6.5) compared with those who did 
not take them (29.2, SD+/-= 5.7). 
Ivanova et al., [20] described how weight gain linked to both 
antidiabetic and antidepressant medications are known risk factors 
in worsening T2DM outcome. Rachdi [21] agreed that 
antidepressants can have a major metabolic impact and can cause 
T2DM, suggesting that the use of sertraline as an antidepressant in 
patients with T2DM may reduce weight gain.  
Pan et al., [22] evaluated this relationship in a cohort study and 
concluded that antidepressants caused considerable weight gain and 
induced impaired glucose homeostasis. The authors concluded that 
the use of antidepressant medications moderately increased the risk 
of T2DM diagnosis regardless of the intensity of weight gain. A 
systematic review by Roopan et al., [23] stated that specific 
antidepressants can have a greater or lesser metabolic effect. They 
noted that when a tricyclic antidepressant was used, closer 
glycaemic monitoring was required to prevent further metabolic 
complications, recommending that the use of selective serotonin 
reuptake inhibitor (SSRI) was preferred in a T2DM patient. Kivimaki 
et al., [24] concurred that the weight gain caused by high doses of 
antidepressants was associated with a doubling of the risk of 
developing T2DM in their study sample. They also highlighted that 
the hyperglycaemic effects of the noradrenergic activity of 
antidepressants increase the risk of diabetes.  
Part 2-real world clinical audit 
A de-identified condition report was gathered from a Medical 
General Practice (GP) in West Midlands, UK, where the GP carried 
out a search on T2DM patients prescribed medications used to treat 
MIH conditions. Total population registered at the practice is 5500. 
Total MIH patients registered in the clinic is 291 patients (alone or 
with co-morbidity), 5.5% of the total clinic population. Total T2DM 
patients registered in the clinic is 71 patients (excluding patients 
who were diet-controlled and those treated with injectable for 
T2DM). There were 28 of these patients (39.5%) identified as 
receiving treatment for MIH condition which is higher than the 
general population (1 in 4 people or 25% experience MIH). This data 
was analysed and compared to the findings from the critical review 
in part 1. 
The population of this practice is diverse in age and ethnicity (fig. 3) 
with Asian being the highest ethnic group (70% vs 30% all others). 
The data showed that in the audited population T2DM diagnosis was 
made at the age of 30 y or over.  
 
 
Fig. 3: T2DM patients’ population by age 
 
The data was further analysed to count the frequencies of conditions 
repeated more than once (table 2). Cardiovascular diseases (CVD) 
were the highest after diabetes followed by neuropathic pain and 
MIH. While erectile dysfunction was reported in four, there was only 
one case of vaginal atrophy in women. 
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Table 2: Common medical condition in patient with T2DM 
Medical condition Female Male 
Erectile dysfunction (ED) 0 4 
Insomnia 1 1 
Parkinson 2 0 
Respiratory 4 4 
Thyroid 4 0 
Dry eye 8 3 
Gastro-oesophageal reflux disease (GORD) 17 7 
Mental illness combined 20 8 
Neuropathic pain 24 6 
Cardiovascular diseases (CVD) 38 24 
Type 2 diabetes mellitus (T2DM) 45 26 
Overall, 73% of the sample audited had 4 or more long-term and chronic conditions (80% of women and 62% of men). The highest numbers of co-
existing conditions were seen in 3 women compared to one man (table 3).  
 
Table 3: Diagnosis of medical condition in diabetic patients 
Gender 1-3 medical conditions 4-6 medical conditions >6 medical conditions Highest comorbidities 
Male 10 13 3 8 
Female 9 33 3 9 
Number of medications per patient was then counted (table 4); with more medications used in men compared to women (42% and 33% 
respectively). 
 
Table 4: Number of medications per patient 
Gender <5 medications 5-9 medications >10 medications Highest polypharmacy 
Male 4 11 11 19 
Female 6 24 15 18 
 
Table 5 illustrates the frequency of prescribing of the top 35 
medications seen in the study sample, with atorvastatin the highest 
medication prescribed in 65% of all audited records. However, it 
was also observed that a large number of medications were 
prescribed to treat T2DM complications such as dry eye, ED, 
neuropathic pain and MIH. 
 
Table 5: Frequency of medication prescribing in the study population 
Most prescribed medication Frequency Most prescribed medication Frequency 
Salbutamol 5 Ca+D 8 
Empagliflozin 5 Citalopram 9 
Clopidogrel 5 Paracetamol 9 
Indapamide 5 Metformin modified release 9 
Pregabalin 5 Losartan 11 
Senna 5 Dapagliflozin 12 
Solifenacin 5 Amlodipine 14 
Tramadol 5 simvastatin 14 
Thyroxine 6 Pantoprazole 17 
Lansoprazole 6 Sertraline 18 
Doxazosin 6 Aspirin 21 
Duloxetine 6 Amitriptyline 24 
Atenolol 6 Linagliptin 24 
Bisoprolol 7 Ramipril 25 
paracetamol/codeine 7 Gliclazide 26 
Omeprazole 8 Metformin 33 
ferrous sulfate 8 Atorvastatin 46 
Table 6 represents the study population diabetes control using their latest HbA1c results. Female patient shows better diabetes control (53%) 
compared to male patients (27%) with the higher HbA1c was not significantly different in both genders. 
 
Table 6: Representation of Hba1c in patient with type 2 diabetes 
Gender  Number of patients HbA1c under<7% HbA1c>7%  highest HbA1c 
Male 26 7 19 10% 
Female 45 24 21 9.7% 
 
T2DM is the fastest growing clinical condition in many countries and 
is having a major impact on the UK NHS budget due to high 
medication use, surgical intervention (amputations) and other 
complications such as blindness and renal failure. The data analysed 
from the literature and the local GP practice shows that T2DM can 
also affect the individual mental state. Overall a clear association can 
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be seen between patients with MIH such as depression and anxiety 
with a diagnosis of T2DM. The studies analysed within this critical 
review and the real-world data demonstrate a strong relationship 
between the MIH and T2DM. The data from the general medical 
practice showed a high prescribing rate of antidepressants. Care is 
required in interpretation as although amitriptyline is an anti-
depressant, it was prescribed here for neuropathic pain and the 
doses used for this indication are general considered inadequate to 
treat depression. It was also found that gender appears to impact on 
diagnosis of MIH, as being higher in females than in the male 
population. However, compared to the general population, mood 
disorders are known to be higher in females than males. 
LIMITATIONS 
Whilst all the studies included investigated the modifying effect, or 
the co-existing effects of the two conditions, the differing study 
designs and analyses used prevented direct comparison. Interest in 
this area is growing fast [25, 26] with new studies regularly 
appearing that should facilitate future meta-analysis. 
Additionally, the patient sample audited was limited to one general 
practice which may not be representative to the entire population of 
patients diagnosed with type 2 diabetes. 
CONCLUSION 
MIH and T2DM are interrelated. Females diagnosed with T2DM are 
at a greater risk of MIH. It is recommended that as soon as a 
diagnosis of T2DM is made clinicians should take active steps to 
prevent, diagnose and treat MIH to reduce its negative effect on 
disease prognosis, patient adherence to pharmacological therapy 
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